The problems with polypharmacy
Interview and article by Christine Clark Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually… read more.
Interview and article by Christine Clark Polypharmacy, or the concomitant use of multiple medicines, is estimated to cost $18 billion and account for 8.6 million hospital admissions annually… read more.
Article written by Gary Finnegan. The European Medicines Agency’s (EMA) key committee, known as the CHMP, has recommended approval of eight medicines at its latest meeting. While the… read more.
Article written by Bruce Sylvester. Treatment with two anti-nausea medications appears to alleviate headaches which took patients to the emergency room in the weeks after the initial injury…. read more.
Abusive alcohol drinking considerably impacts human health. Alcoholism, better defined as Alcohol Use Disorders (AUD), includes a group of pathological entities related to alcohol-induced damage. Individuals with AUD… read more.
Interview and article by Christine Clark. Community pharmacies are at the heart of their communities and can contribute to the Vac4covid study by signposting patients to the website,… read more.
Interview and article by Christine Clark. Gavin Dobson, Clinical Trials Pharmacist at MEMO Research explains the practical details of the Vac4covid study. The Vac4covid study will recruit at… read more.
Interview and article by Christine Clark. The Vac4covid study has been designed to provide important data about the safety and effectiveness of covid-19 vaccines. IMI interviewed Mr Gavin… read more.
ASHP (American Society of Health-System Pharmacists) today announced the publication of two landmark reports that articulate a futuristic vision for pharmacy practice, including expanded roles for the pharmacy enterprise… read more.
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.
Article written by Gary Finnegan. The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting:
BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of… read more.
Pfizer announced that the FDA accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.